Published in Semin Thromb Hemost on January 01, 1999
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br J Clin Pharmacol (2001) 1.14
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol (2010) 1.13
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol (2010) 1.06
A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol (2006) 0.96
Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp (2003) 0.87
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86
Critical appraisal of ticagrelor in the management of acute coronary syndrome. Ther Clin Risk Manag (2011) 0.85
Antithrombotic treatment and atrial fibrillation. BMJ (1992) 5.33
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med (2000) 3.90
Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke (1999) 2.89
Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis. Circulation (2001) 2.43
Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol (1990) 2.43
Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther (1978) 2.41
Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation (1996) 2.32
Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J (2000) 2.30
Narcotic analgesics and delayed gastric emptying during labour. Lancet (1975) 2.24
Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol (1975) 2.18
Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J (1999) 2.08
Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J (2000) 2.08
Acute exercise and markers of endothelial injury in peripheral arterial disease. Eur J Vasc Endovasc Surg (1997) 2.07
Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia (2011) 2.06
Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol (2001) 1.96
ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ (1996) 1.85
Drugs, diseases and altered gastric emptying. Clin Pharmacokinet (1976) 1.77
Adverse effects of opioid analgesic drugs. Br J Anaesth (1987) 1.72
Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth (1981) 1.71
Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1986) 1.64
Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) (2001) 1.63
Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J (1997) 1.60
The relationship between blood viscosity and blood pressure in a random sample of the population aged 55 to 74 years. Eur Heart J (1993) 1.60
Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J (1996) 1.59
Hypoxaemia during outpatient dental anaesthesia. Anaesthesia (1989) 1.50
Tissue plasminogen activator inhibition in diabetes mellitus. Diabetes Care (1989) 1.45
Association of fibrinolytic tests with outcome of acute upper-gastrointestinal-tract bleeding. Lancet (1993) 1.45
Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet (1992) 1.44
Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia. J Thromb Haemost (2007) 1.43
Relation between extent of coronary artery disease and blood viscosity. Br Med J (1980) 1.42
In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer. Thromb Haemost (1989) 1.39
A model to test the potency of inhalation anaesthetics. Br J Anaesth (1989) 1.39
Paracetamol and aspirin absorption from Safapryn and Safapryn-Co. Br J Clin Pharmacol (1979) 1.39
Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J (1995) 1.38
Blood rheology in vitro and in vivo. Baillieres Clin Haematol (1987) 1.36
Dental disease, fibrinogen and white cell count; links with myocardial infarction? Scott Med J (1993) 1.36
Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol (1983) 1.34
Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem (2000) 1.34
Relation of atrial fibrillation and high haematocrit to mortality in acute stroke. Lancet (1983) 1.34
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol (1996) 1.29
The effects of age and cigarette-smoking on blood and plasma viscosity in men. Scott Med J (1980) 1.28
How periodontal disease may contribute to cardiovascular disease. Periodontol 2000 (2000) 1.26
Blood rheology in arterial disease. Clin Sci (Lond) (1986) 1.23
Fatal retroperitoneal haemorrhage complicating anticoagulant therapy. Postgrad Med J (1979) 1.21
HTLV-III seropositivity in European haemophiliacs exposed to Factor VIII concentrate imported from the USA. Lancet (1984) 1.20
Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci (1982) 1.18
Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol (1999) 1.17
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol (1997) 1.17
Guidelines for the use of thrombolytic therapy. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Blood Coagul Fibrinolysis (1995) 1.16
Concurrent drug therapy in patients undergoing surgery. Anaesthesia (1987) 1.16
Measurement of FEV1 and FVC. Comparison of a pocket spirometer with the Vitalograph. Anaesthesia (1988) 1.15
Diagnosis and treatment of venous thromboembolism by consultants in Scotland. Br Med J (Clin Res Ed) (1983) 1.14
Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet (1993) 1.14
Effect of induction of anaesthesia with etomidate on corticosteroid synthesis in man. Br J Anaesth (1985) 1.13
Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Lond) (1995) 1.13
Laboratory diagnosis of congenital coagulation defects. Clin Haematol (1979) 1.13
Changes in neutrophil deformability following in vitro smoke exposure: mechanism and protection. Am J Respir Cell Mol Biol (1992) 1.13
Immunological abnormalities in haemophilia: are they caused by American factor VIII concentrate? Br Med J (Clin Res Ed) (1983) 1.12
Pharmacokinetics of propofol (diprivan) in elderly patients. Br J Anaesth (1988) 1.12
Blood viscosity as a factor in sensorineural hearing impairment. Lancet (1986) 1.12
Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J (1981) 1.10
Increased platelet aggregates in vascular and nonvascular illness: correlation with plasma fibrinogen and effect of ancrod. Thromb Res (1979) 1.10
Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. N Engl J Med (1986) 1.10
Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth (1981) 1.09
Effect of anaesthesia on gastric motility and emptying. Br J Anaesth (1984) 1.09
Influence of age, systemic blood pressure, smoking, and blood viscosity on orbital blood velocities. Br J Ophthalmol (1995) 1.09
Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Br Heart J (1993) 1.09
Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol (1999) 1.08
Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost (1999) 1.08
Paracetamol absorption from Paramax, Panadol and Solpadeine. Br J Clin Pharmacol (1983) 1.08
Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial. Lancet (1983) 1.06
Blood rheology in general medicine and surgery. Baillieres Clin Haematol (1987) 1.06
Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation (1998) 1.05
Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study. Arterioscler Thromb Vasc Biol (2000) 1.05
Effect of cisapride on morphine-induced delay in gastric emptying. Br J Anaesth (1987) 1.04
Ketamine disposition in children and adults. Br J Anaesth (1983) 1.03
Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis (1993) 1.02
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
Effect of different rates of infusion of propofol for induction of anaesthesia in elderly patients. Br J Anaesth (1990) 1.01
Gastric emptying and drug absorption before surgery. Br J Anaesth (1984) 1.01
Who should take aspirin for primary prophylaxis of coronary heart disease? Heart (2001) 1.01
White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost (1985) 0.99
Platelet aggregation studies in whole human blood. Thromb Res (1983) 0.99
Platelet aggregation, haematocrit, and fibrinogen. Lancet (1985) 0.99
Gastric contents at induction of anaesthesia. Is a 4-hour fast necessary? Br J Anaesth (1983) 0.98
Blood rheology and thrombosis. Clin Haematol (1981) 0.97
The effects of acute smoking on platelet behaviour, fibrinolysis and haemorheology in habitual smokers. Thromb Haemost (1984) 0.96
Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's syndrome. Prostaglandins Leukot Med (1985) 0.96
The lupus anticoagulant and its role in thrombosis. Blood Rev (1987) 0.95
Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice cultures of normal and scleroderma skin fibroblasts. Eur J Cell Biol (1992) 0.95
Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study. Eur J Endocrinol (2010) 0.95
Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis (1998) 0.95
Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. Atherosclerosis (2000) 0.94
Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release. Heart (2002) 0.94
Prognostic value of beta-thromboglobulin in patients with transient cerebral ischaemia. Lancet (1983) 0.94
Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol (1997) 0.93
Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost (1999) 0.93
Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes (Lond) (2007) 0.93